Yayın:
Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome

dc.contributor.authorOnat, Altan
dc.contributor.authorHergenc, Guelay
dc.contributor.authorOzhan, Hakan
dc.contributor.authorKaya, Zekeriya
dc.contributor.authorBulur, Serkan
dc.contributor.authorAyhan, Erkan
dc.contributor.authorCan, Guenay
dc.date.accessioned2026-06-27T13:09:47Z
dc.date.issued2008
dc.description.abstractAim To assess (i) the association between lipoprotein(a) [Lp(a)] with the likelihood of coronary heart disease and metabolic syndrome (MS) and (ii) its covariates in Turkish adults. Methods Cross-sectional evaluation of 1309 adults, who had serum Lp(a) determinations by Behring nephelometry, and followed for a mean 1.0 year. MS was defined by ATPIII criteria modified for male abdominal obesity. Results Mean age of the sample was 56.8 +/- 11.3 years. After adjustment for sex, age, and smoking status, log-transformed Lp(a) levels were associated significantly with coronary heart disease likelihood in both sexes combined [odds ratio: 1.53 (95% confidence interval: 1.06; 2.20)]. This association persisted after additional adjustment for MS [odds ratio: 1.57 (95% confidence interval: 1.09; 2.26)]. The Lp(a) mid-tertile (5-17 mg/dl), accompanied by significantly lower serum triglycerides than the two remaining tertiles, was inversely associated significantly with MS in either sex; in women, this association was independent of waist circumference. In a linear regression comprising seven variables, excepting total cholesterol, only gamma-glutamyltransferase in women (P=0.002) and waist circumference (P=0.057) in men were inverse covariates of modest magnitude of Lp(a). Conclusion Coronary heart disease likelihood, significantly associated with Lp(a) concentrations, is independent of MS and insulin resistance. Suggestive evidence was provided that intermediary Lp(a) concentrations, when accompanied by the presence of MS, could accelerate progression of vascular disease, especially in women.en
dc.description.urihttps://doi.org/10.1097/mca.0b013e3282f399cf
dc.identifier.doi10.1097/mca.0b013e3282f399cf
dc.identifier.eissn1473-5830
dc.identifier.endpage131
dc.identifier.issn0954-6928
dc.identifier.issue3
dc.identifier.pubmed18418227
dc.identifier.startpage125
dc.identifier.urihttps://hdl.handle.net/20.500.14981/50591
dc.identifier.volume19
dc.identifier.wos000255571200001
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofCORONARY ARTERY DISEASE
dc.rightsopenAccess
dc.subjectcoronary heart disease
dc.subjectinsulin resistance
dc.subjectlipoprotein(a)
dc.subjectmetabolic syndrome
dc.subjectSERUM LIPOPROTEIN(A)
dc.subjectLP(A) CONCENTRATIONS
dc.subjectINSULIN-RESISTANCE
dc.subjectRISK-FACTOR
dc.subjectAPOLIPOPROTEIN(A)
dc.subjectPOPULATION
dc.subjectPHENOTYPES
dc.subjectAMERICANS
dc.subjectLIPIDS
dc.subjectCardiovascular System & Cardiology
dc.titleLipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar